Aclaris Therapeutics, Inc. continued its evolution in 2025 with meaningful progress in clinical-stage drug development, notably advancing its ATI-052 bispecific antibody for atopic dermatitis into Phase 1b trials. Despite no product revenue, the company improved operating results, cutting its net loss nearly by half versus 2024. Operating cash flow deficits reflect ongoing investments in R&D amid modest capital expenditures. The firm’s capacity to secure reimbursement, navigate regulatory approvals, and forge strategic partnerships will critically shape its path toward commercialization. Elevated risks around third-party dependencies, regulatory compliance, and supply chain exposures remain material as Aclaris pursues clinical milestones and financial stabilization.